NCT03076203 - Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

January 13, 2020

Study Completion Date

November 7, 2022

Conditions

Prostate Carcinoma Metastatic to the BoneStage IV Prostate AdenocarcinomaHormone-refractory Prostate Cancer

Interventions

DRUG

Niraparib

Given orally

RADIATION

Radium Ra 223 Dichloride

Given intravenously

Trial Locations (6)

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

University of Alabama, Birmingham

University of Chicago Medical Center, Chicago

Tulane University, New Orleans

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston